[go: up one dir, main page]

MA35268B1 - 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie - Google Patents

1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie

Info

Publication number
MA35268B1
MA35268B1 MA36688A MA36688A MA35268B1 MA 35268 B1 MA35268 B1 MA 35268B1 MA 36688 A MA36688 A MA 36688A MA 36688 A MA36688 A MA 36688A MA 35268 B1 MA35268 B1 MA 35268B1
Authority
MA
Morocco
Prior art keywords
treatment
piperazino
deuterated
phenylindanes
schizophrenia
Prior art date
Application number
MA36688A
Other languages
English (en)
Inventor
Morten Jorgensen
Peter Hongaard Andersen
Klaus Gjervig Jensen
Mette Graulund Hvenegaard
Lassina Badolo
Mikkel Fog Jacobsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA35268B1 publication Critical patent/MA35268B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des 1-pipérazino-3-phénylindanes deutérés et des sels de ceux-ci ayant une activité au niveau de récepteurs d1 et d2 dopaminergiques, ainsi qu'au niveau des récepteurs 5ht2 dans le système nerveux central, des médicaments comprenant de tels composés en tant que principes actifs, l'utilisation de tels composés dans le traitement de maladies du système nerveux central, et des méthodes de traitement comprenant l'administration de tels composés.
MA36688A 2011-06-20 2014-01-16 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie MA35268B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21
PCT/IB2012/001386 WO2012176066A1 (fr) 2011-06-20 2012-06-19 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie

Publications (1)

Publication Number Publication Date
MA35268B1 true MA35268B1 (fr) 2014-07-03

Family

ID=46682855

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36688A MA35268B1 (fr) 2011-06-20 2014-01-16 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie

Country Status (40)

Country Link
US (9) US8575174B2 (fr)
EP (4) EP4215512A1 (fr)
JP (1) JP5668177B2 (fr)
KR (2) KR101939546B1 (fr)
CN (1) CN103649019B (fr)
AP (1) AP3310A (fr)
AR (1) AR086987A1 (fr)
AU (1) AU2012273657B2 (fr)
BR (1) BR112013031702B1 (fr)
CA (1) CA2837820C (fr)
CL (1) CL2013003646A1 (fr)
CO (1) CO6821965A2 (fr)
CR (1) CR20130654A (fr)
CY (2) CY1118158T1 (fr)
DK (2) DK2720989T3 (fr)
DO (1) DOP2013000305A (fr)
EA (1) EA024651B1 (fr)
EC (1) ECSP14013155A (fr)
ES (3) ES2601213T3 (fr)
GE (1) GEP201706655B (fr)
GT (1) GT201300304A (fr)
HR (2) HRP20161348T1 (fr)
HU (2) HUE044043T2 (fr)
IL (1) IL229640B (fr)
JO (1) JO3128B1 (fr)
LT (2) LT2720989T (fr)
MA (1) MA35268B1 (fr)
MD (1) MD4538C1 (fr)
ME (2) ME02513B (fr)
MX (1) MX339552B (fr)
MY (1) MY196998A (fr)
PE (2) PE20141113A1 (fr)
PH (1) PH12013502598A1 (fr)
PL (2) PL3135656T3 (fr)
PT (2) PT2720989T (fr)
RS (2) RS58546B1 (fr)
SI (2) SI2720989T1 (fr)
SM (2) SMT201900179T1 (fr)
TW (3) TWI659741B (fr)
WO (1) WO2012176066A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3135656T3 (pl) * 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
PT3679018T (pt) 2017-09-07 2022-04-05 Otsuka Pharma Co Ltd Processo industrial de monoalquilação de um nitrogénio de piperidina em derivados de piperidina com alquilo deuterado
CN112930341A (zh) * 2018-10-29 2021-06-08 H.隆德贝克有限公司 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐
CN113056457B (zh) 2018-12-03 2025-06-20 H.隆德贝克有限公司 用于治疗cns疾病的前药
EA202191731A1 (ru) * 2018-12-21 2021-10-28 Консерт Фармасьютикалз, Инк. Дейтерированные формы и производные волинансерина
ES3040728T3 (en) * 2019-03-13 2025-11-04 Otsuka Pharma Co Ltd Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine
CN117164518A (zh) * 2022-05-26 2023-12-05 四川大学 一种制备氘代咪唑类化合物的方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196284A (en) 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
JPS62501009A (ja) 1984-12-04 1987-04-23 サンド・アクチエンゲゼルシヤフト メバロノラクトンのインデン同族体及びその誘導体
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
JP2001517666A (ja) 1997-09-23 2001-10-09 藤沢薬品工業株式会社 チアゾール誘導体
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MEP2408A (xx) * 2003-08-18 2010-02-10 Lundbeck & Co As H Trans-1-(6-hloro-3 fenilindan-1-1l)-3,3-dimetilpiperazin
MXPA06001938A (es) 2003-08-18 2006-05-17 Lundbeck & Co As H Trans-1-(6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina.
EP1773772B1 (fr) 2004-06-08 2010-06-02 NSAB, Filial af NeuroSearch Sweden AB, Sverige Nouvelles phenylpiperidines/piperazines disubstitues utilisees comme modulateurs de neurotransmission de la dopamine
RU2366654C2 (ru) 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
EP1853575A1 (fr) 2005-02-16 2007-11-14 H. Lundbeck A/S Sels tartrate et malate de la trans-1-[(1r,3s)-6-chloro-3-phenylindan-1-yl]-3,3-dimethylpiperazine
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
ES2396365T3 (es) 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
CA2631581C (fr) 2005-12-01 2011-05-03 Auspex Pharmaceuticals, Inc. Phenetylamines substituees a l'activite serotoninergique et/ou norepinephrinergique
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
WO2008086158A1 (fr) 2007-01-04 2008-07-17 Smithkline Beecham Corporation Composés benzodihydroquinazoline utilisés comme inhibiteurs de kinases pi3
WO2008128166A1 (fr) 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Dérivés deutériés de composés 4-(6-fluoro-1,2-benzisoxazol-3-yl) pipéridine
CA2686545C (fr) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Composes substitues de morpholinyle
EP1997479A1 (fr) 2007-05-31 2008-12-03 Helm AG Formulations stabilisées contentant du candesartan cilexetil amorphe pour l'administration orale
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
AU2009243813B2 (en) 2008-05-07 2014-05-29 H. Lundbeck A/S Method for treating cognitive deficits
US20110178094A1 (en) 2008-10-03 2011-07-21 H. Lundbeck A/S Oral Formulation
WO2010062656A2 (fr) 2008-10-28 2010-06-03 Concert Pharmaceuticals Inc. Composés d’acide 2-propylpentanoïque deutérés
JP2012506904A (ja) 2008-10-28 2012-03-22 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 難水溶性成分のためのメソ多孔性材料賦形剤
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
US8557994B2 (en) 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
WO2011047315A1 (fr) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Benzimidazoles substitués
WO2011059080A1 (fr) * 2009-11-16 2011-05-19 第一三共株式会社 Dérivé de diamine substitué par un isotope
AU2010339689B2 (en) 2010-01-07 2015-02-19 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
CN103209949B (zh) 2010-11-09 2016-08-10 株式会社钟化 卤化茚酮类及使用其的光学活性茚满酮类或光学活性茚满醇类的制造方法
CN103429577A (zh) 2011-01-07 2013-12-04 H.隆德贝克有限公司 4-((1r,3s)-6-氯-3-苯基-茚满-1-基)-1,2,2-三甲基哌嗪和1-((1r,3s)-6-氯-3-苯基-茚满-1-基)-3,3-二甲基哌嗪的拆分方法
EP2693876B1 (fr) 2011-04-08 2020-01-15 Sphaera Pharma Pte. Ltd Réactifs de méthylformyle substitué et procédé d'utilisation de ceux-ci pour modifier des propriétés physicochimiques et/ou pharmacocinétiques de composés
PL3135656T3 (pl) * 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
AU2013326850B2 (en) 2012-10-04 2017-09-21 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma

Also Published As

Publication number Publication date
US20120322811A1 (en) 2012-12-20
US20170158650A1 (en) 2017-06-08
IL229640A0 (en) 2014-01-30
TWI627956B (zh) 2018-07-01
MD4538C1 (ro) 2018-07-31
CL2013003646A1 (es) 2014-07-04
MX339552B (es) 2016-05-31
SMT201600383B (it) 2017-01-10
EA201490045A1 (ru) 2014-07-30
JP5668177B2 (ja) 2015-02-12
PH12013502598A1 (en) 2014-02-10
ECSP14013155A (es) 2014-02-28
US9012453B2 (en) 2015-04-21
LT2720989T (lt) 2016-11-25
CO6821965A2 (es) 2013-12-31
EP3508468B1 (fr) 2023-01-18
KR20180075717A (ko) 2018-07-04
BR112013031702B1 (pt) 2021-11-03
EP3135656B1 (fr) 2019-02-27
IL229640B (en) 2018-02-28
BR112013031702A2 (pt) 2016-12-13
ME02513B (fr) 2017-02-20
TW201722895A (zh) 2017-07-01
JP2014520140A (ja) 2014-08-21
PE20141113A1 (es) 2014-09-25
PE20150928A1 (es) 2015-06-26
ME03375B (fr) 2020-01-20
EP2720989A1 (fr) 2014-04-23
PT3135656T (pt) 2019-05-03
HK1197228A1 (zh) 2015-01-09
PT2720989T (pt) 2016-11-07
TW201311248A (zh) 2013-03-16
US20220119362A1 (en) 2022-04-21
PL2720989T3 (pl) 2017-05-31
WO2012176066A1 (fr) 2012-12-27
NZ618222A (en) 2015-03-27
US20130281436A1 (en) 2013-10-24
AU2012273657A1 (en) 2013-12-12
US9617231B2 (en) 2017-04-11
CR20130654A (es) 2014-03-24
HUE030883T2 (en) 2017-06-28
CY1118158T1 (el) 2017-06-28
GEP201706655B (en) 2017-04-25
EP3135656A1 (fr) 2017-03-01
JO3128B1 (ar) 2017-09-20
CA2837820C (fr) 2019-02-19
GT201300304A (es) 2015-01-16
MD4538B1 (ro) 2017-12-31
DK3135656T3 (en) 2019-04-23
DOP2013000305A (es) 2014-02-28
CN103649019A (zh) 2014-03-19
ES2719145T3 (es) 2019-07-08
KR101879474B1 (ko) 2018-07-17
TWI659741B (zh) 2019-05-21
RS55304B1 (sr) 2017-03-31
CA2837820A1 (fr) 2012-12-27
MX2013014849A (es) 2014-03-31
PL3135656T3 (pl) 2019-07-31
SI2720989T1 (sl) 2016-11-30
AP2013007338A0 (en) 2013-12-31
LT3135656T (lt) 2019-04-25
CN103649019B (zh) 2015-09-16
ES2939477T3 (es) 2023-04-24
US10118907B2 (en) 2018-11-06
TWI614234B (zh) 2018-02-11
US11059798B2 (en) 2021-07-13
RS58546B1 (sr) 2019-05-31
EP2720989B1 (fr) 2016-08-10
SMT201900179T1 (it) 2019-05-10
KR20140041567A (ko) 2014-04-04
SI3135656T1 (sl) 2019-05-31
MD20140004A2 (en) 2014-05-31
US10501427B2 (en) 2019-12-10
CY1121514T1 (el) 2020-05-29
US12116355B2 (en) 2024-10-15
HRP20190593T1 (hr) 2019-05-17
ES2601213T3 (es) 2017-02-14
HRP20161348T1 (hr) 2016-12-02
TW201902481A (zh) 2019-01-16
HUE044043T2 (hu) 2019-09-30
MY196998A (en) 2023-05-17
AR086987A1 (es) 2014-02-05
US20250250244A1 (en) 2025-08-07
DK2720989T3 (en) 2016-11-28
US20190031631A1 (en) 2019-01-31
EA024651B1 (ru) 2016-10-31
AU2012273657B2 (en) 2016-07-21
US8575174B2 (en) 2013-11-05
EP3508468A1 (fr) 2019-07-10
US20150307458A1 (en) 2015-10-29
US20200131143A1 (en) 2020-04-30
AP3310A (en) 2015-06-30
US20160068497A1 (en) 2016-03-10
US9216961B2 (en) 2015-12-22
EP4215512A1 (fr) 2023-07-26
KR101939546B1 (ko) 2019-01-16

Similar Documents

Publication Publication Date Title
MA35268B1 (fr) 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA38147B1 (fr) Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
MA37888A1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
MA33334B1 (fr) Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
BR112012032282A2 (pt) administração transdérmica de memantina
EA201400567A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
MA33295B1 (fr) Nouvelle formulation de diclofénac
EA201391662A1 (ru) Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA35407B1 (fr) Modulateurs allostériques positifs des récepteurs nicotiniques d'acétylcholine
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
EP2563794A4 (fr) Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
MA38425B1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
MA34805B1 (fr) Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
FR2981933B1 (fr) Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
MA39020A1 (fr) Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique
EP2862573A4 (fr) Composition pour le traitement ou la prévention de maladies causées par une perméabilité vasculaire, contenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif